InvestorsHub Logo

fabius

05/31/17 2:22 AM

#27448 RE: E Star Capital #27447

This is reinforcing the idea of Mallinckrodt as the preferred partner for Rexista/Prodras + Regabatin. They are exiting all the low margin businesses.

To be closely monitored to have an idea of possible IPCI partnership announcement. Mallinck now knows Intelli pipeline and IF they liked it...

zoomlik

05/31/17 7:18 AM

#27452 RE: E Star Capital #27447

If acquires does not have Serq, it is a plus for them

If acquirer is PAR, they will have two diff generics for Serq in market .. I am not sure if that is a negative

So, in either case MNK is motivated to launch or get more value

fmgrana

05/31/17 9:21 AM

#27454 RE: E Star Capital #27447

Makes one wonder why they would partner with IPCI on three generics if they intend to sell off the this area of the business unless they wanted just wanted to 'puff' it up with a few more drugs to enhance the sale of the generics unit.